MX2016010171A - Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas. - Google Patents
Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas.Info
- Publication number
- MX2016010171A MX2016010171A MX2016010171A MX2016010171A MX2016010171A MX 2016010171 A MX2016010171 A MX 2016010171A MX 2016010171 A MX2016010171 A MX 2016010171A MX 2016010171 A MX2016010171 A MX 2016010171A MX 2016010171 A MX2016010171 A MX 2016010171A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- population
- methods
- serum
- culture medium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente se proporcionan métodos para la fabricación de células T; en ciertas modalidades se proporcionan métodos para fabricar células T que expresan un receptor de superficie celular que reconoce una porción antigénica específica en la superficie de una célula objetivo; dichos métodos pueden incluir, pero no se limitan a, los pasos de (1) enriquecer una población de linfocitos obtenidos de un sujeto donador; (2) estimular la población de linfocitos con uno o más agentes estimuladores de la célula T para producir una población de células T activadas, en donde la estimulación se realiza en un sistema cerrado utilizando un medio de cultivo libre de suero; (3) transducir la población de células T activadas con un vector viral que comprende una molécula de ácido nucleico que codifica para el receptor de superficie celular, usando una transducción de ciclo sencillo para producir una población de células T transducidas, en donde la transducción se realiza en un sistema cerrado utilizando un medio de cultivo libre de suero; y (4) expandir la población de células T transducidas durante un tiempo predeterminado para producir una población de células T diseñadas, en donde la expansión se realiza en un sistema cerrado utilizando un medio de cultivo libre de suero; también se proporcionan en la presente poblaciones de células T diseñadas producidas por los métodos que describen en la presente y sus composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461935833P | 2014-02-04 | 2014-02-04 | |
| PCT/US2015/014520 WO2015120096A2 (en) | 2014-02-04 | 2015-02-04 | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016010171A true MX2016010171A (es) | 2017-02-15 |
Family
ID=53778605
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010171A MX2016010171A (es) | 2014-02-04 | 2015-02-04 | Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas. |
| MX2023010870A MX2023010870A (es) | 2014-02-04 | 2023-09-14 | Métodos para producir células t autólogas útiles para tratar enfermedades malignas de las células b y otros cánceres y sus composiciones |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010870A MX2023010870A (es) | 2014-02-04 | 2023-09-14 | Métodos para producir células t autólogas útiles para tratar enfermedades malignas de las células b y otros cánceres y sus composiciones |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20150344844A1 (es) |
| EP (3) | EP3102609B1 (es) |
| JP (5) | JP2017505819A (es) |
| KR (5) | KR102729771B1 (es) |
| CN (4) | CN120536375A (es) |
| AU (4) | AU2015214145A1 (es) |
| CA (1) | CA2937938A1 (es) |
| CY (2) | CY1127499T1 (es) |
| DK (1) | DK3102609T3 (es) |
| ES (1) | ES2989838T3 (es) |
| FI (2) | FI3102609T3 (es) |
| FR (1) | FR25C1009I1 (es) |
| HR (1) | HRP20241270T1 (es) |
| HU (2) | HUE069092T2 (es) |
| IL (4) | IL312867A (es) |
| LT (2) | LT3102609T (es) |
| MX (2) | MX2016010171A (es) |
| NO (1) | NO2025012I1 (es) |
| PL (1) | PL3102609T3 (es) |
| PT (1) | PT3102609T (es) |
| RS (1) | RS66199B1 (es) |
| SI (1) | SI3102609T1 (es) |
| SM (1) | SMT202400465T1 (es) |
| WO (1) | WO2015120096A2 (es) |
Families Citing this family (170)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2741757B1 (en) | 2011-09-11 | 2018-05-16 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
| EP2831109B1 (en) | 2012-03-28 | 2017-12-06 | Gadeta B.V. | Combinatorial gamma 9 delta 2 t cell receptor chain exchange |
| NZ725201A (en) | 2014-04-25 | 2018-05-25 | Bluebird Bio Inc | Improved methods for manufacturing adoptive cell therapies |
| SI3151672T1 (sl) | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| EA036379B1 (ru) | 2014-12-12 | 2020-11-02 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| JP2018510627A (ja) * | 2015-03-10 | 2018-04-19 | レイデン ユニバーシティ メディカル センター | メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用 |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| US11479755B2 (en) | 2015-12-07 | 2022-10-25 | 2Seventy Bio, Inc. | T cell compositions |
| CN109414455B (zh) | 2016-04-01 | 2023-01-20 | 凯德药业股份有限公司 | Bcma结合分子及其使用方法 |
| KR20200068750A (ko) | 2016-04-01 | 2020-06-15 | 카이트 파마 인코포레이티드 | 키메라 수용체 및 그의 사용 방법 |
| PT3436079T (pt) | 2016-04-01 | 2021-10-06 | Kite Pharma Inc | Recetores de antigénios quiméricos e de células t e métodos de uso |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| JP2019525898A (ja) | 2016-06-10 | 2019-09-12 | ガデタ・ベー・フェー | ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法 |
| JP7483373B2 (ja) * | 2016-07-29 | 2024-05-15 | ジュノー セラピューティクス インコーポレイテッド | 複製可能ウイルスの存在または非存在を評価するための方法 |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP2020500031A (ja) * | 2016-10-11 | 2020-01-09 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用 |
| KR20240005168A (ko) | 2016-11-04 | 2024-01-11 | 2세븐티 바이오, 인코포레이티드 | 항-bcma car t 세포 조성물 |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| WO2018136566A1 (en) * | 2017-01-18 | 2018-07-26 | F1 Oncology, Inc. | Methods of transducing and expanding immune cells and uses thereof |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| SG11201908271WA (en) * | 2017-03-14 | 2019-10-30 | Juno Therapeutics Inc | Methods for cryogenic storage |
| WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
| US20200071773A1 (en) | 2017-04-12 | 2020-03-05 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| JP7486953B2 (ja) | 2017-05-18 | 2024-05-20 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | 細胞標的化療法のための組成物および方法 |
| JP7245177B2 (ja) | 2017-06-07 | 2023-03-23 | シージェン インコーポレイテッド | 低減した表面フコシル化を有するｔ細胞、及びそれを作製及び使用する方法 |
| WO2018232195A1 (en) | 2017-06-14 | 2018-12-20 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2019011879A1 (en) | 2017-07-09 | 2019-01-17 | Rainer Henning | THERAPEUTIC AGENT FOR THE TREATMENT OF CAPILLARY LEAK SYNDROME |
| US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
| CN109423525A (zh) * | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种表达car的逆转录病毒放行检测方法 |
| CN109420168A (zh) * | 2017-08-31 | 2019-03-05 | 海南诺倍尔生态医学科学研究院有限公司 | 一种抑制wt1基因突变的生物制剂制备技术 |
| CA3248436A1 (en) | 2017-09-01 | 2025-02-21 | Lonza Walkersville, Inc. | END-TO-END AUTOMATION OF CELL THERAPY |
| EP3695408B1 (en) | 2017-10-02 | 2026-01-21 | The Broad Institute, Inc. | Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer |
| JP7585034B2 (ja) | 2017-10-18 | 2024-11-18 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| CA3084470A1 (en) * | 2017-10-18 | 2019-04-25 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
| US11866731B2 (en) * | 2017-11-10 | 2024-01-09 | Chineo Medical Technology Co., Ltd | Modified immune cells and uses thereof |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH |
| SG11202004512XA (en) | 2017-11-15 | 2020-06-29 | Novartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
| BR112020014446A2 (pt) | 2018-01-15 | 2020-12-29 | Pfizer Inc. | Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| CN112055744A (zh) | 2018-02-09 | 2020-12-08 | 环球生命科技咨询美国有限责任公司 | 用于在生物处理系统中的流体管线管理的装置 |
| EP3749753B1 (en) * | 2018-02-09 | 2025-04-02 | Immatics US, Inc. | Methods for manufacturing t cells |
| US10889792B2 (en) | 2018-02-09 | 2021-01-12 | Global Life Sciences Solutions Usa Llc | Cell expansion vessel systems and methods |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| US11149244B2 (en) | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
| CA3095920A1 (en) | 2018-04-10 | 2019-10-17 | Amgen Inc. | Chimeric receptors to dll3 and methods of use thereof |
| CN108575986A (zh) * | 2018-04-25 | 2018-09-28 | 广州莱德尔生物科技有限公司 | 一种保存液组合物及其应用 |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| US12227763B2 (en) | 2018-05-11 | 2025-02-18 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| KR102544086B1 (ko) | 2018-06-01 | 2023-06-16 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t 세포 요법 |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| JP7524157B2 (ja) | 2018-07-22 | 2024-07-29 | ミノヴィア セラピューティクス リミテッド | 脳疾患のミトコンドリア増強療法 |
| JP7458368B2 (ja) | 2018-07-22 | 2024-03-29 | ミノヴィア セラピューティクス リミテッド | 筋疾患のミトコンドリア増強療法 |
| US12551504B2 (en) | 2018-07-22 | 2026-02-17 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of pancreatic diseases |
| WO2020021536A1 (en) | 2018-07-22 | 2020-01-30 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy for primary mitochondrial diseases |
| JP2021531288A (ja) | 2018-07-22 | 2021-11-18 | ミノヴィア セラピューティクス リミテッド | 眼疾患のミトコンドリア増強療法 |
| US12329781B2 (en) | 2018-07-22 | 2025-06-17 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of renal diseases |
| CA3107383A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
| CA3107378A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy |
| SG11202101014XA (en) * | 2018-08-02 | 2021-02-25 | Kite Pharma Inc | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CA3109959A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| SG11202102986XA (en) | 2018-09-24 | 2021-04-29 | Southwest Res Inst | Three-dimensional bioreactors |
| JP7396777B2 (ja) | 2018-09-28 | 2023-12-12 | オクタン バイオテック インコーポレーテッド | 磁気分離 |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| SG11202104524YA (en) | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN118931967A (zh) * | 2018-12-07 | 2024-11-12 | 亘喜生物科技（上海）有限公司 | 用于免疫疗法的组合物和方法 |
| KR102840400B1 (ko) | 2018-12-12 | 2025-08-04 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| IL284214B2 (en) | 2018-12-21 | 2025-03-01 | Octane Biotech Inc | Carousel for modular biologic production units |
| KR20210108406A (ko) | 2018-12-21 | 2021-09-02 | 론자 워커스빌 아이엔씨. | 바이러스 벡터의 자동화된 생산 |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| IL285288B2 (en) | 2019-02-08 | 2026-04-01 | Lonza Walkersville Inc | Cell concentration methods and devices for use in automated bioreactors |
| EP3927847A4 (en) | 2019-02-22 | 2023-04-19 | Garvan Institute of Medical Research | Methods of modulating immune response via snvs of a20 that can "tune" the immune system of a subject |
| US20220152150A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| WO2020180591A1 (en) | 2019-03-01 | 2020-09-10 | Allogene Therapeutics, Inc. | Dll3 targeting chimeric antigen receptors and binding agents |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| EP3942025A1 (en) | 2019-03-21 | 2022-01-26 | Novartis AG | Car-t cell therapies with enhanced efficacy |
| WO2020191378A1 (en) | 2019-03-21 | 2020-09-24 | Allogene Therapeutics, Inc. | METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CN113767165A (zh) | 2019-04-24 | 2021-12-07 | W.L.戈尔及同仁股份有限公司 | 高耐久性可渗透性含氟聚合物细胞培养袋 |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| JP7664180B2 (ja) | 2019-04-26 | 2025-04-17 | アロジーン セラピューティクス，インコーポレイテッド | リツキシマブ耐性キメラ抗原受容体およびその用途 |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| US20200384027A1 (en) | 2019-05-03 | 2020-12-10 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| CA3142108A1 (en) * | 2019-05-28 | 2020-12-03 | Miltenyi Biotec B.V. & Co. KG | Method for generation of genetically modified t cells |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| CN114729292A (zh) | 2019-10-24 | 2022-07-08 | 奥克泰生物科技股份有限公司 | 具有经改进的细胞接触表面的细胞培养室 |
| IL292665B2 (en) | 2019-11-06 | 2026-02-01 | Kite Pharma Inc | Chimeric antigen receptor T cell therapy |
| EP4058563A4 (en) | 2019-11-11 | 2023-12-06 | Lonza Walkersville, Inc. | QUALITY CONTROL PROCEDURES FOR AUTOMATED CELL PROCESSING |
| PH12022551291A1 (en) | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| EP4073103A1 (en) | 2019-12-11 | 2022-10-19 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| US12180444B2 (en) | 2019-12-30 | 2024-12-31 | Saint-Gobain Performance Plastics Corporation | Containers and methods for cell transduction |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| WO2021167908A1 (en) | 2020-02-17 | 2021-08-26 | Board Of Regents, The University Of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| KR20220147109A (ko) | 2020-02-27 | 2022-11-02 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
| KR20220146530A (ko) | 2020-02-27 | 2022-11-01 | 노파르티스 아게 | 키메라 항원 수용체-발현 세포의 제조 방법 |
| CA3172402A1 (en) * | 2020-03-31 | 2021-10-07 | Minovia Therapeutics Ltd. | Mitochondria-enriched genetically engineered cells and uses thereof |
| EP4133057A4 (en) * | 2020-04-10 | 2025-04-16 | Southwest Research Institute | Three-dimensional bioreactor for viral vector production |
| US12241086B2 (en) | 2020-04-15 | 2025-03-04 | Amgen Inc. | Process for generating genetically engineered autologous T cells |
| EP4135724A1 (en) * | 2020-04-15 | 2023-02-22 | Amgen Inc. | Process for generating genetically engineered autologous t cells |
| US12378521B2 (en) | 2020-04-15 | 2025-08-05 | Amgen Inc. | Method for enhancing production of genetically engineered autologous T cells |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| KR102859550B1 (ko) | 2020-08-20 | 2025-09-16 | 에이투 바이오쎄라퓨틱스, 인크. | Ceacam 양성 암을 치료하기 위한 조성물 및 방법 |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| AU2021328478A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| KR102923890B1 (ko) * | 2020-08-20 | 2026-02-05 | 주식회사 아모라이프사이언스 | T 세포 배양기 및 이를 이용한 t 세포 배양 시스템 |
| US20230302155A1 (en) | 2020-08-21 | 2023-09-28 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| US20220155299A1 (en) | 2020-10-28 | 2022-05-19 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
| AU2022212090A1 (en) | 2021-01-28 | 2023-07-06 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| TW202245811A (zh) | 2021-02-03 | 2022-12-01 | 美商異基因治療有限公司 | 用於ｃａｒ ｔ細胞藥物產品的調配物與製程 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| IL305571A (en) | 2021-03-11 | 2023-10-01 | Kite Pharma Inc | Improving the function of immune system cells |
| KR20230167063A (ko) * | 2021-04-08 | 2023-12-07 | 다케다 야쿠힌 고교 가부시키가이샤 | T-세포 활성화 방법 |
| EP4330381A1 (en) | 2021-04-27 | 2024-03-06 | Novartis AG | Viral vector production system |
| CA3227581A1 (en) | 2021-07-29 | 2023-02-02 | Takeda Pharmaceutical Company Limited | Engineered immune cell that specifically targets mesothelin and uses thereof |
| JP2024531364A (ja) | 2021-08-20 | 2024-08-29 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| US12539515B2 (en) | 2021-10-28 | 2026-02-03 | Southwest Research Institute | Devices for cell separation |
| CN115025217B (zh) * | 2022-05-13 | 2023-05-05 | 广东齐美医药生物科技集团有限公司 | 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途 |
| WO2023230276A1 (en) | 2022-05-27 | 2023-11-30 | Kite Pharma, Inc. | Compositions and methods for preparing engineered lymphocytes for cell therapy |
| CN115039763A (zh) * | 2022-07-15 | 2022-09-13 | 北京大学第三医院（北京大学第三临床医学院） | 一种免疫细胞冻存液 |
| US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| CN120112650A (zh) | 2022-10-26 | 2025-06-06 | 诺华股份有限公司 | 慢病毒配制品 |
| KR20250097844A (ko) | 2022-10-28 | 2025-06-30 | 카이트 파마 인코포레이티드 | 면역요법의 효능 향상 및 지속적인 반응 |
| CN120051287A (zh) | 2022-10-28 | 2025-05-27 | 凯德药业股份有限公司 | 工程化淋巴细胞的加速施用 |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| AU2024364039A1 (en) * | 2023-10-18 | 2026-04-16 | Tq Therapeutics Gmbh | A method of manufacturing a cellular therapy product and respective kits and devices |
| WO2025096517A1 (en) | 2023-11-01 | 2025-05-08 | Kite Pharma, Inc. | Factors for optimizing immunotherapy efficacy |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
| US20250297219A1 (en) | 2024-02-08 | 2025-09-25 | Kite Pharma, Inc. | Methods for generating engineered lymphocytes with enriched t memory stem cells |
| US20250262300A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| WO2025259578A1 (en) | 2024-06-11 | 2025-12-18 | Kite Pharma, Inc. | Methods for generating engineered lymphocytes |
| US20260009001A1 (en) | 2024-07-08 | 2026-01-08 | Kite Pharma, Inc. | Systems and methods for applying mechanical force to living cells to generate a phenotypic response |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008042814A2 (en) * | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| CN102046780A (zh) * | 2008-03-27 | 2011-05-04 | 宝生物工程株式会社 | 转染的细胞的生产方法 |
| WO2010080032A2 (en) * | 2009-01-09 | 2010-07-15 | Stichting Het Nederlands Kanker Instituut | Bead-assisted viral transduction |
| EP2694549B1 (en) * | 2011-04-08 | 2018-08-15 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| WO2013040557A2 (en) * | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| EP2594632A1 (en) * | 2011-11-18 | 2013-05-22 | Miltenyi Biotec GmbH | Method and device for cell modification |
| JP6661544B2 (ja) * | 2014-04-24 | 2020-03-11 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子改変したｔ細胞の自動生成法 |
-
2015
- 2015-02-04 JP JP2016567484A patent/JP2017505819A/ja active Pending
- 2015-02-04 PL PL15746399.3T patent/PL3102609T3/pl unknown
- 2015-02-04 HR HRP20241270TT patent/HRP20241270T1/hr unknown
- 2015-02-04 EP EP15746399.3A patent/EP3102609B1/en active Active
- 2015-02-04 KR KR1020227027811A patent/KR102729771B1/ko active Active
- 2015-02-04 RS RS20241262A patent/RS66199B1/sr unknown
- 2015-02-04 IL IL312867A patent/IL312867A/en unknown
- 2015-02-04 KR KR1020247037315A patent/KR20240164967A/ko active Pending
- 2015-02-04 KR KR1020207007771A patent/KR20200032763A/ko not_active Ceased
- 2015-02-04 CN CN202510648656.2A patent/CN120536375A/zh active Pending
- 2015-02-04 LT LTEPPCT/US2015/014520T patent/LT3102609T/lt unknown
- 2015-02-04 CN CN202510648653.9A patent/CN120536374A/zh active Pending
- 2015-02-04 DK DK15746399.3T patent/DK3102609T3/da active
- 2015-02-04 EP EP23155129.2A patent/EP4215603A1/en active Pending
- 2015-02-04 WO PCT/US2015/014520 patent/WO2015120096A2/en not_active Ceased
- 2015-02-04 MX MX2016010171A patent/MX2016010171A/es unknown
- 2015-02-04 PT PT157463993T patent/PT3102609T/pt unknown
- 2015-02-04 CN CN201580016764.2A patent/CN106459915A/zh active Pending
- 2015-02-04 ES ES15746399T patent/ES2989838T3/es active Active
- 2015-02-04 EP EP17154769.8A patent/EP3208330A1/en not_active Withdrawn
- 2015-02-04 CN CN202111599342.6A patent/CN114395530A/zh active Pending
- 2015-02-04 KR KR1020217004191A patent/KR20210020165A/ko not_active Ceased
- 2015-02-04 FI FIEP15746399.3T patent/FI3102609T3/fi active
- 2015-02-04 US US14/614,400 patent/US20150344844A1/en not_active Abandoned
- 2015-02-04 SI SI201532039T patent/SI3102609T1/sl unknown
- 2015-02-04 KR KR1020167024014A patent/KR20160113295A/ko not_active Ceased
- 2015-02-04 IL IL290744A patent/IL290744B2/en unknown
- 2015-02-04 HU HUE15746399A patent/HUE069092T2/hu unknown
- 2015-02-04 CA CA2937938A patent/CA2937938A1/en active Pending
- 2015-02-04 AU AU2015214145A patent/AU2015214145A1/en not_active Abandoned
- 2015-02-04 SM SM20240465T patent/SMT202400465T1/it unknown
-
2016
- 2016-08-03 IL IL247095A patent/IL247095B/en unknown
-
2018
- 2018-06-18 US US16/011,292 patent/US20190032011A1/en not_active Abandoned
-
2020
- 2020-01-22 JP JP2020007980A patent/JP7087011B2/ja active Active
- 2020-02-21 AU AU2020201292A patent/AU2020201292B2/en active Active
-
2021
- 2021-04-14 IL IL282352A patent/IL282352B/en unknown
-
2022
- 2022-06-08 JP JP2022092616A patent/JP7532445B2/ja active Active
- 2022-08-31 AU AU2022224780A patent/AU2022224780B2/en active Active
-
2023
- 2023-09-14 MX MX2023010870A patent/MX2023010870A/es unknown
- 2023-12-21 US US18/393,414 patent/US20240158748A1/en active Pending
-
2024
- 2024-07-31 JP JP2024124165A patent/JP7779960B2/ja active Active
- 2024-11-14 CY CY20241100801T patent/CY1127499T1/el unknown
-
2025
- 2025-02-19 FR FR25C1009C patent/FR25C1009I1/fr active Active
- 2025-02-20 FI FIC20250010C patent/FIC20250010I1/fi unknown
- 2025-02-20 AU AU2025201205A patent/AU2025201205A1/en active Pending
- 2025-02-25 NO NO2025012C patent/NO2025012I1/no unknown
- 2025-02-26 LT LTPA2025510C patent/LTPA2025510I1/lt unknown
- 2025-02-27 HU HUS2500012C patent/HUS2500012I1/hu unknown
- 2025-02-27 CY CY2025007C patent/CY2025007I1/el unknown
- 2025-11-20 JP JP2025200372A patent/JP2026035657A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010171A (es) | Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas. | |
| MX2019004708A (es) | Celulas que presentan antigeno artificial manipulado por ingenieria para expansion linfocitica infiltrante de tumores. | |
| MX2020013977A (es) | Proteínas quiméricas transmembrana y usos de las mismas. | |
| MX2019003683A (es) | Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos. | |
| MX2024009690A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| EA201791443A1 (ru) | Естественные киллерные клетки и их применения | |
| MX2021001523A (es) | Procesos para generar células modificadas y composiciones de las mismas. | |
| MX2019006340A (es) | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. | |
| BR112018068746A2 (pt) | vesículas de membrana terapêutica | |
| MY189819A (en) | Genetically modified cells and uses thereof | |
| MX2019006010A (es) | Administracion viral de neoantigenos. | |
| CO2018004937A2 (es) | Células asesinas naturales y células ilc3 y usos de las mismas | |
| MX2017003625A (es) | Reactivos y metodos para identificar, enriquecer y/o expander celulas t especificas de antigeno. | |
| MX2018005274A (es) | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. | |
| BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
| PE20160950A1 (es) | Biomarcadores de cancer y usos de los mismos | |
| UY36554A (es) | ARNi VARIANTE | |
| BR112021008738A2 (pt) | Processo para produzir células t geneticamente construídas | |
| EA201590488A1 (ru) | Способы модификации клеток-хозяев | |
| BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
| MA39867A (fr) | Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive | |
| ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
| MX2021009967A (es) | Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas. | |
| MX2019011138A (es) | Antagonistas del receptor de hidrocarburo de arilo y sus usos. | |
| EA201891459A1 (ru) | Новое поколение антигенспецифических tcr |